Country: কানাডা
ভাষা: ইংরেজি
সূত্র: Health Canada
IBUPROFEN; METHOCARBAMOL
TEVA CANADA LIMITED
M03BA53
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
200MG; 500MG
TABLET
IBUPROFEN 200MG; METHOCARBAMOL 500MG
ORAL
18/40
OTC
CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS
Active ingredient group (AIG) number: 0248961001; AHFS:
CANCELLED PRE MARKET
2015-11-25
IMPORTANT: PLEASE READ 1 | P a g e PRODUCT MONOGRAPH REGULAR STRENGTH ANALGESIC & MUSCLE RELAXANT CAPLETS METHOCARBAMOL AND IBUPROFEN TABLETS 500 MG/200 MG THERAPEUTIC CLASSIFICATION MUSCLE RELAXANT / ANALGESIC TEVA CANADA LIMITED, Date of Preparation: 30 Novopharm Court March 5, 2013 Toronto, Canada M1B 2K9 Control# 161027 IMPORTANT: PLEASE READ 2 | P a g e TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION..............................................3 SUMMARY PRODUCT INFORMATION .......................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ..................................................................................................3 ADVERSE REACTIONS..................................................................................................10 DRUG INTERACTIONS..................................................................................................12 DOSAGE AND ADMINISTRATION..............................................................................15 OVERDOSAGE ...............................................................................................................16 ACTION AND CLINICAL PHARMACOLOGY ...........................................................18 STORAGE AND STABILITY.........................................................................................22 SPECIAL HANDLING INSTRUCTIONS ......................................................................22 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................22 PART II: SCIENTIFIC INFORMATION....................................................................21 PHARMACEUTICAL INFORMATION..........................................................................21 CLINICAL TRIALS..........................................................................................................23 DETAILED PHARMACOLOGY........................................ সম্পূর্ণ নথি পড়ুন